AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers Squibb (NYSE:BMY) has tapped Cristian Massacesi, as executive vice president, chief medical officer, and head of development, effective August 1, 2025. Massacesi most recently served as ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.

The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth strategies offset patent expiries.

The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb’s Fundamentals Over Recent Years. Bristol Myers Squibb’s revenue increased from $26 billion in 2019 to $46 billion in 2022, partly aided by its Celgene CELG acquisition in ...

Bristol Myers Squibb’s revenue of $11.0 billion in Q3 was down 2% y-o-y, primarily due to lower sales of Revlimid. The company has seen market share gains for some of its drugs, including its ...